Physician profile
Robert C Siudmak
NPI 1073792180
$2,234.95
in general payments reported to CMS, 2019-2025
20 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $335 · 2021: $453 · 2022: $165 · 2023: $132 · 2024: $70.00 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $781.30 | 2019-2025 | Slynd |
| Abbvie INC. | $501.37 | 2019-2025 | Lo Loestrin Fe |
| Therapeuticsmd, INC. | $206.93 | 2019-2022 | |
| Agile Therapeutics, INC. | $119.31 | 2021 | |
| Hologic Sales and Service, LLC | $95.07 | 2021-2024 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $86.20 | 2024-2025 | Veozah |
| Evofem Biosciences, INC. | $67.82 | 2020-2025 | Solosec, Phexx, Phexxi |
| Lupin INC. | $53.86 | 2019-2021 | |
| Myovant Sciences INC. | $46.01 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $37.39 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $37.14 | 2022-2023 | |
| Allergan, INC. | $36.69 | 2019-2020 | |
| Duchesnay USA Incorporated | $31.43 | 2019 | |
| Biogen, INC. | $30.47 | 2025 | Zurzuvae |
| Avion Pharmaceuticals | $23.37 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $18.97 | 2019 | |
| Millicent US INC | $18.13 | 2019 | |
| Pfizer INC. | $16.09 | 2023 | |
| Becton, Dickinson and Company | $14.11 | 2024 | Bd Onclarity |
| Sumitomo Pharma America, INC. | $13.29 | 2023 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Siudmak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.